Spoken Alpha
LIFECORE BIOMEDICAL, INC. DE
Lifecore Biomedical manufactures pharmaceutical-grade hyaluronic acid and provides contract development and manufacturing services for complex sterile injectable products in syringes, vials, and cartridges.
LIFECORE BIOMEDICAL, INC. DE is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $158.2M market cap.
LFCR beat consensus EPS by 0.1% in Q1 FY2027, reported Aug 30, 2026.
17 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for LFCR.
$ curl https://api.spokenalpha.com/v1/companies/LFCRFAQ
Spoken Alpha indexes LFCR's earnings call transcripts at https://spokenalpha.com/companies/LFCR. Each call links to attributed speakers and parsed analyst Q&A.
LIFECORE BIOMEDICAL, INC. DE (LFCR) held its most recent earnings call on 2026-03-16, covering fiscal Q4 2025.
LIFECORE BIOMEDICAL, INC. DE (LFCR) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2027 | 2026-08-30 | $-0.19 | $-0.22 | +14.6% | — | — | — | EODHD |
| Q4 FY2026 | 2026-08-04 | $-0.19 | $-0.17 | -11.8% | $34.2M | — | — | EODHD |
| Q3 FY2026 | 2026-04-06 | $-0.16 | $-0.23 | +30.4% | $23.2M | — | — | EODHD |
| Q2 FY2026 | 2025-12-31 | $0.00 | $-0.16 | +100.0% | — | — | — | EODHD |
| Q1 FY2026 | 2025-11-05 | $-0.43 | $-0.30 | -43.3% | $31.1M | — | — | EODHD |
| Q4 FY2025 | 2025-08-06 | $-0.10 | $-0.09 | -11.1% | $36.4M | — | — | EODHD |
| Q3 FY2025 | 2025-04-02 | $-0.47 | $-0.15 | -100.0% | $35.2M | — | — | EODHD |
| Q2 FY2025 | 2025-01-01 | $-0.20 | $-0.30 | +33.3% | $32.6M | — | — | EODHD |
| Q1 FY2025 | 2024-10-03 | $-0.37 | $-0.46 | +19.6% | $24.7M | — | — | EODHD |
| Q4 FY2024 | 2024-08-25 | $-0.17 | $-0.12 | -41.7% | $37.9M | — | — | EODHD |
| Q3 FY2024 | 2024-02-28 | $0.42 | $0.13 | +100.0% | $25.5M | — | — | EODHD |
| Q2 FY2024 | 2023-12-28 | $-0.13 | $-0.23 | +43.5% | $30.1M | — | — | EODHD |
| Q1 FY2024 | 2023-11-13 | $-1.19 | $-0.23 | -100.0% | $24.5M | — | — | EODHD |
| Q4 FY2023 | 2023-08-30 | $-0.11 | $-0.07 | -57.1% | $26.5M | — | — | EODHD |
| Q2 FY2023 | 2023-03-15 | $-0.42 | $-0.11 | -100.0% | $21.9M | — | — | EODHD |
| Q1 FY2023 | 2022-10-05 | $-0.32 | $-0.13 | -100.0% | $47.6M | — | — | EODHD |
| Q4 FY2022 | 2022-08-09 | $-0.01 | $-0.01 | 0.0% | $47.6M | — | — | EODHD |
| Q3 FY2022 | 2022-04-04 | $-0.08 | $-0.03 | -100.0% | $37.4M | — | — | EODHD |
| Q2 FY2022 | 2022-01-04 | $-0.22 | $-0.09 | -100.0% | $43.5M | — | — | EODHD |
| Q1 FY2022 | 2021-09-28 | $-0.23 | $-0.12 | -91.7% | $128.8M | — | — | EODHD |
Source: EODHD. LFCR reported actuals as published; sparse fields render as —.